Pacira: Safer than Opioids? (05-19-2016)

 Comments Off on Pacira: Safer than Opioids? (05-19-2016)
May 202016
 
Pacira: Safer than Opioids? (05-19-2016)

The move away from opiods is gaining momentum, explains biotech sector John McCamant, editor The Medical Technology Stock Letter.

Top Picks 2016: Pharmaceuticals (1-28-2016)

 Comments Off on Top Picks 2016: Pharmaceuticals (1-28-2016)
Jan 292016
 
Top Picks 2016: Pharmaceuticals (1-28-2016)

Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his top pick for 2016-The Medicines Company. #MDCO

Top Picks 2016: Anthera (1-15-2016)

 Comments Off on Top Picks 2016: Anthera (1-15-2016)
Jan 212016
 
Top Picks 2016: Anthera (1-15-2016)

Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his top pick for 2016-Anthera Pharmaceuticals. #ANTH

2015’s Top Performers (1-12-2016)

 Comments Off on 2015’s Top Performers (1-12-2016)
Jan 122016
 
2015's Top Performers (1-12-2016)

Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his two biotech stock picks for 2015 that have risen 33% and 41%. #NVAX #MDCO

2015’s Top Performers (12-30-2015)

 Comments Off on 2015’s Top Performers (12-30-2015)
Dec 312015
 
2015's Top Performers (12-30-2015)

Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his two biotech stock picks for 2015 that have risen 33% and 41%. #NVAX #MDCO

Biotech Bets: A Mispriced Trio (11-9-2015)

 Comments Off on Biotech Bets: A Mispriced Trio (11-9-2015)
Nov 092015
 
Biotech Bets: A Mispriced Trio  (11-9-2015)

Recent volatility has created an environment for biotech stocks in which company fundamentals are mispriced relative to their stock prices, according to John McCamant. Here, the editor of The Medical Technology Stock Letter discusses the current state of the biotech market and highlights a trio of well-positioned stocks currently being undervalued by the market.

Life Sciences Report (9-16-15)

 Comments Off on Life Sciences Report (9-16-15)
Sep 162015
 
Life Sciences Report (9-16-15)

An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.

MoneyShow – Top Picks Mid-Year Winners: Jay Silverman (7-6-15)

 Comments Off on MoneyShow – Top Picks Mid-Year Winners: Jay Silverman (7-6-15)
Jul 062015
 
MoneyShow - Top Picks Mid-Year Winners: Jay Silverman (7-6-15)

In January, MoneyShow asked all of the nation’s leading advisors to select a favorite stock for 2015. In this special series of interviews we are talking with the five advisors who had the top performing stock picks as of mid-year. Here, we talk with Jay Silverman, editor of The Medical Technology Stock Letter, to discuss a top performing biotechnology company.

MoneyShow: Biotech Catalysts (6-22-15)

 Comments Off on MoneyShow: Biotech Catalysts (6-22-15)
Jun 302015
 
MoneyShow:  Biotech Catalysts (6-22-15)

Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.

MarketWatch (5-13-15)

 Comments Off on MarketWatch (5-13-15)
May 142015
 
MarketWatch (5-13-15)

Biotech buyout fever is going to continue. But be careful: You need to pick the right companies and hold them for years. Find out the reasons biotech buyouts will continue and stock picks from biotech analysts including John McCamant of BioInvest.

Forbes (5-13-15)

 Comments Off on Forbes (5-13-15)
May 142015
 
Forbes (5-13-15)

Gene Marcial of Forbes interviews John McCamant of the Medical Technology Stock Letter to discuss an attractive M&A play in the Biotech Space.

Life Sciences Report (5-12-15)

 Comments Off on Life Sciences Report (5-12-15)
May 132015
 
Life Sciences Report (5-12-15)

An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.

Wide World of Stocks (4-9-15)

 Comments Off on Wide World of Stocks (4-9-15)
Apr 092015
 
Wide World of Stocks (4-9-15)

Guest John McCamant, editor of the Medical Technology Stock Letter (MTSL), joins Wide World of Stocks host Damon Roberts to discuss a potential biotech bubble, merger mania, and opportunity with ZIOPHARM (NASDAQ: ZIOP)

MoneyShow: A Trio of Biotech Favorites (4-6-15)

 Comments Off on MoneyShow: A Trio of Biotech Favorites (4-6-15)
Apr 062015
 
MoneyShow: A Trio of Biotech Favorites (4-6-15)

Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.